Vaginal pharmaceutical composition comprising miconazole and luliconazole or salts thereof
By developing vaginal pharmaceutical compositions containing miconazole and luliconazole, combined with pharmaceutical excipients, the lack of combination of miconazole and luliconazole in existing products has been solved, and effective treatment and high compliance with vaginal fungal infections have been achieved. sex, reducing side effects.
Patent Information
- Application Number
- CN202380033637.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-17
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-12
AI Technical Summary
Among the existing vaginal fungal infection treatment products, the combination of miconazole and luliconazole is missing, resulting in low compliance and many side effects in patients, which cannot effectively prevent and treat vaginal infection.
开发包含0.1%-10% w/w的咪康唑或其盐和0.01-5% w/w的卢立康唑的阴道药物组合物,结合药学上可接受的赋形剂,如润滑剂、乳化剂和防腐剂,通过特定的制备方法制成乳霜剂型,用于治疗阴道感染。
This composition has broad-spectrum antifungal activity when treating vaginal fungal infection, with minimal side effects, improves patient compliance and treatment effect, broadens the antifungal activity spectrum, and reduces therapeutic toxicity.
Smart Images

Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] The present invention relates to a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof for treating vaginal infection.
[0002] In particular, the present invention relates to vaginal pharmaceutical compositions for treating vaginal infections and methods for their preparation.
[0003] More specifically, the present invention relates to a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof and at least one pharmaceutically acceptable excipient, a method for preparing the same, and a method for treating vaginal infections using the same. Background Art
[0004] Vaginal yeast infection is a common genital fungal infection. About 20% of women are infected once a year. About 75% of women have at least one infection in their lifetime. Vulvovaginal candidiasis is a more common form of yeast infection. Yeast infection, also known as candidiasis, candidiasis or candidal vaginitis, is one of the most common vaginal infections. These vaginal infections are caused by fungal yeasts of the genus Candida (Candida) (formerly known as Monilia), and specifically species include C. albicans, C. tropicalis, C. psuedotropicalis, C. glabrata, C. parapsilosis, C. krusei, C. stellatoidea, Bacteroides fragilis and Gardnerella vaginalis. Generally speaking, 90% of yeast infections are caused by Candida albicans.
[0005] These Candida fungal microorganisms normally grow and multiply in low concentrations in the mouth, gastrointestinal tract, and vagina, coexisting with the normal biological flora in these areas without adversely affecting health or physiological function. Lactobacilli keep their growth in check. However, if the system is out of balance, these bacteria cannot function effectively. This leads to an overgrowth of yeast, which causes symptoms of vaginal yeast infection such as vaginal itching, swelling around the vagina, burning during urination or intercourse, pain during intercourse, soreness, redness, rash, and vaginal discharge.
[0006] Types of vaginal infections are yeast infection, bacterial vaginosis, trichomoniasis, sexually transmitted infections (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, noninfectious vaginitis, and atrophic vaginitis.
[0007] For intravaginal treatment, various types of tablets, capsules, foams, pessaries, ointments, and creams containing various conventional drugs in conventional delivery systems have been introduced for short-term or long-term therapy. More effective treatments for Candida infections generally involve applying an anti-yeast drug to the vagina and repeating the intravaginal administration of the drug at selected intervals over several days or weeks.
[0008] Miconazole nitrate is an imidazole synthetic antifungal agent. It selectively affects the integrity of fungal cell membranes. Chemically, miconazole nitrate is 1-[2,4-dichloro-β-{(2,4-dichlorobenzyl)oxy}phenethyl]imidazole mononitrate, and its molecular weight is 479.15. Its empirical formula is C 18 H 14 C l4 N2O•HNO3. Miconazole nitrate is represented by the compound of structural formula I.
[0009]
[0010] Formula I
[0011] Miconazole nitrate is a white to almost white powder. It is soluble in water and organic solvents such as ethanol, DMSO and dimethylformamide (DMF), propylene glycol or pyridine.
[0012] Miconazole nitrate 2% and 4% vaginal creams were approved in the USA on February 15, 1991 and March 30, 1998, respectively, under the trade names "MONISTAT 7" and "MONISTAT 3", and are indicated for the treatment of vaginal yeast infections and the relief of external itching and irritation associated therewith.
[0013] Luliconazole is an imidazole antifungal drug. Chemically, luliconazole is (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl acetonitrile. Luliconazole is the R enantiomer and contains a chiral center. The double bond adjacent to the dithiolane group is in the E configuration. Its molecular weight is 354.28. Its empirical formula is C 14 H9Cl2N3S2. Luliconazole is represented by the compound of structural formula II.
[0014]
[0015] Formula II
[0016] Luliconazole is a pale yellow to yellow solid. It is slightly soluble in water, soluble in acetonitrile and dimethyl sulfoxide, and slightly soluble in chloroform and methanol.
[0017] Luliconazole topical cream (1%) was approved in the United States on November 14, 2013, under the trade name “Luzu” and is indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age or older.
[0018] U.S. Patent No. 10086008 discloses a topical paste comprising one or more antifungal agents, an excipient inert powder and a pharmaceutically acceptable topical carrier. The patent application generally discloses antifungal agents such as clotrimazole, ketoconazole, miconazole, oxiconazole, econazole, luliconazole, terbinafine, nystatin, fluconazole, voriconazole, itraconazole, caspofungin, micafungin, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, sertaconazole, efinaconazole, enilaconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), pimaricin, griseofulvin, haloprogin, tolnaftate, undecylenate or any combination thereof. In addition, the patent application specifically discloses an antifungal composition containing terbinafine or terbinafine hydrochloride; however, it does not teach or disclose a vaginal composition of miconazole and luliconazole.
[0019] US Patent No. 5514698 discloses a long-acting viscous antifungal vaginal cream composition comprising an imidazole antifungal drug selected from miconazole, econazole, terconazole, saperconazole, itraconazole, ketoconazole and clotrimazole; however, it does not teach or disclose a vaginal composition of miconazole and luliconazole.
[0020] PCT Publication No. WO2011121604 discloses a liquid vaginal spray dosage form comprising a therapeutically effective amount of at least one antifungal agent and lactic acid; wherein the antifungal agent is selected from miconazole, ketoconazole, clotrimazole, econazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, griseofulvin, fluconazole, forsifofconazole, itraconazole, posaconazole, voriconazole, amorolfine, butenafine, naftifine, terbinafine, terbinafine, natamycin, nystatin, amphotericin B, thiabendazole, anidulafungin, caspofungin, micafungin, flucytosine; however, it does not teach or disclose a vaginal combination of miconazole and luliconazole.
[0021] Currently, commercially available market products in the treatment of vaginal fungal infections include butoconazole nitrate (as a 2% vaginal cream), clotrimazole (as a 1% topical cream), miconazole (as a 4% vaginal cream, 100 mg and 200 mg strength suppositories), terconazole (as 0.4%, 0.8% strength creams and 80 mg strength suppositories), fluconazole (as tablets of 50 mg, 100 mg, 150 mg, 200 mg strengths).
[0022] For luliconazole, the most common adverse reactions of products known in the prior art are application site reactions, while for miconazole the most common adverse reactions are allergic contact dermatitis, cellulitis, irritation, burning, and maceration; therefore, these products cannot provide patient compliance when treating vaginal fungal infections.
[0023] There is no combination of miconazole and luliconazole in the marketed products, and thus there is an unmet need to develop a vaginal pharmaceutical composition comprising a combination of miconazole or a salt thereof and luliconazole or a salt thereof.
[0024] Vaginal infections are very common because there are many factors that disturb the vaginal flora, which makes the vagina less resistant to infections, such as but not limited to bacterial and fungal infections. Therefore, if it inhibits harmful bacteria and fungi, it has important clinical significance for the prevention and treatment of reproductive tract infections.
[0025] Therefore, there is an unmet need in the art to develop a vaginal pharmaceutical composition comprising miconazole and luliconazole for treating vaginal infections that has minimal side effects, has a broad spectrum of antifungal activity, is effective in treating vaginal fungal infections and provides better patient compliance.
[0026] Therefore, the applicant of the present invention has invented a novel vaginal pharmaceutical composition comprising miconazole or its salt and luliconazole or its salt for treating vaginal infection, which is effective, has a broad spectrum of activity against vaginal infection, and has minimal side effects and better patient compliance.
[0027] Purpose of the Invention
[0028] The object of the present invention is to provide a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0029] An object of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof.
[0030] The object of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infection, which comprises miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0031] The object of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infection, comprising:
[0032] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0033] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0034] iii) 0.1-15 % w / w of a lubricant;
[0035] iv) 0.1-25 % w / w of an emulsifier;
[0036] v) 0.1-10 % w / w of a co-emulsifier;
[0037] vi) 0.001-6 % w / w of a preservative; and
[0038] vii) Adequate amount of vehicle.
[0039] The object of the present invention is to provide a vaginal pharmaceutical composition comprising:
[0040] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0041] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0042] iii) 0.1-15 % w / w of a lubricant;
[0043] iv) 0.1-25 % w / w of an emulsifier;
[0044] v) 0.1-10 % w / w of a co-emulsifier;
[0045] vi) 0.001-6 % w / w of a preservative; and
[0046] vii) Adequate amount of vehicle.
[0047] A further object of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infection comprising miconazole or a salt thereof and luliconazole or a salt thereof, which has a broad spectrum of antifungal activity in treating vaginal fungal infections.
[0048] A further object of the present invention is to provide a method for preparing a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof, the method comprising:
[0049] (a) Water phase: dissolve the preservative in purified water, mix and heat at an appropriate temperature;
[0050] (b) lipid phase: mix the co-emulsifier, emulsifier, lubricant and preservative and heat at an appropriate temperature;
[0051] (c) cooling the lipid phase of step (b) at a suitable temperature and mixing the two active pharmaceutical ingredients (API) for 5-10 minutes;
[0052] (d) adding step (c) to step (a) and mixing for 10 minutes to achieve emulsification; and
[0053] (e) The cream obtained in step (d) was slowly mixed and cooled at room temperature. Summary of the invention
[0054] In a main aspect, the present invention discloses a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0055] In one aspect, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof.
[0056] In another aspect, the present invention relates to a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0057] In another aspect, the present invention relates to a vaginal pharmaceutical composition for treating vaginal infection, comprising:
[0058] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0059] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0060] iii) 0.1-15 % w / w of a lubricant;
[0061] iv) 0.1-25 % w / w of an emulsifier;
[0062] v) 0.1-10 % w / w of a co-emulsifier;
[0063] vi) 0.001-6 % w / w of a preservative; and
[0064] vii) QS medium
[0065] In another aspect, the present invention relates to a vaginal pharmaceutical composition comprising:
[0066] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0067] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0068] iii) 0.1-15 % w / w of a lubricant;
[0069] iv) 0.1-25 % w / w of an emulsifier;
[0070] v) 0.1-10 % w / w of a co-emulsifier;
[0071] vi) 0.001-6 % w / w of a preservative; and
[0072] vii) Vehicles of qs.
[0073] In another aspect, the present invention provides a method for preparing a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof, comprising:
[0074] (a) Water phase: dissolve the preservative in purified water, mix and heat at an appropriate temperature;
[0075] (b) lipid phase: mix the co-emulsifier, emulsifier, lubricant and preservative and heat at an appropriate temperature;
[0076] (c) cooling the lipid phase of step (b) at a suitable temperature and mixing the two active pharmaceutical ingredients (API) for 5-10 minutes;
[0077] (d) emulsifying by adding step (c) to step (a) and mixing for 10 minutes; and
[0078] (e) The cream obtained in step (d) was slowly mixed and cooled at room temperature.
[0079] Another aspect of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof. DETAILED DESCRIPTION OF THE INVENTION
[0081] As used herein, the terms "composition" or "pharmaceutical composition" or "vaginal pharmaceutical composition" or "topical pharmaceutical composition" are synonymous and include dosage forms such as topicals, creams, ointments, and the like.
[0082] As used herein, the terms "infection" or "vaginal infection" or "fungal infection" or "yeast infection" or "vaginal yeast infection" or "vaginal fungal infection" are synonymous.
[0083] In the following specification and claims, reference will be made to a number of terms which shall be defined to have the following meanings: The singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0084] The present invention relates to a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0085] The present invention relates to a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof.
[0086] The miconazole and luliconazole of the present invention may exist in the form of a free base or a pharmaceutically acceptable salt thereof.
[0087] The term "miconazole" is used in a broad sense and includes not only "miconazole" itself, but also pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs and various crystalline and amorphous forms thereof.
[0088] The salt of miconazole can be selected from nitrate, maleate, hemifumarate, hemisuccinate, etc.; preferably, miconazole nitrate is used.
[0089] The concentration of miconazole or its salt is at least 0.1%; preferably 0.1% to 10%; more preferably 0.25% to 5% by total weight of the composition.
[0090] The term "luliconazole" is used in a broad sense and includes not only "luliconazole" itself, but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs and various crystalline and amorphous forms thereof.
[0091] The salt of luliconazole can be selected from formic acid, acetic acid, citric acid, tartaric acid, bitartaric acid, benzoic acid, lactic acid, malic acid, fumaric acid, succinic acid, gluconic acid, pamoic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid, and the like.
[0092] The concentration of luliconazole or its salt is at least 0.01% by weight of the composition; preferably 0.01 to 5% by weight; more preferably 0.1% to 4% by weight.
[0093] As used in the present invention, the term "fungal infection" may be selected from vaginal candidiasis (Candida) or candidiasis or candidal vaginitis caused by fungus-like yeasts of the Candida genus (formerly known as Candida), and specifically fungal infections caused by species including Candida albicans, Candida tropicalis, Candida pseudotropicalis, Candida glabrata, Candida parapsilosis, Candida krusei and Candida asteroides.
[0094] As used in the present invention, the vaginal infection may be the group of vaginal infections: yeast infection, bacterial vaginosis, trichomoniasis, sexually transmitted infection (STI), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis and atrophic vaginitis.
[0095] The antifungal spectrum of miconazole nitrate includes many fungi, including yeasts and dermatophytes. It is particularly active against Candida species (C. guilliermondii and Candida tropicalis), Trichophyton species (Trichophyton mentagrophytes and Trichophyton rubrum), Epidermophyton species (Epidermophyton floccosum), Microsporum species (M. canis), Pityrosporon orbiculare (Malassezia furfur), and also has some activity against Gram-positive bacteria (Staphylococcus aureus).
[0096] Luliconazole has a spectrum of antifungal activity that includes dermatophytes, yeasts, and some other fungi. It is particularly active against Trichophyton species (Trichophyton rubrum, Trichophyton mentagrophytes and Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton violaceum, Microsporum canis and Microsporum gypseum, Epidermophyton floccosum), Candida albicans, Malassezia furfur, Malassezia restricta, Malassezia slooffiae, and Malassezia sympodioides.
[0097] Miconazole and luliconazole of the present invention act as antifungal agents that inhibit / prevent vaginal fungal infections.
[0098] Miconazole acts by inhibiting the 14α-demethylation of lanosterol, thus leading to the inhibition of ergosterol synthesis in fungal cell membranes. In addition, miconazole has been shown to induce reactive oxygen species in fungal biofilms, showing MIC values of ≥256 µM against Candida spp.
[0099] Luliconazole works by inhibiting the synthesis of ergosterol by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme by azoles results in a decrease in the amount of ergosterol (a component of fungal cell membranes) and a corresponding accumulation of lanosterol.
[0100] The vaginal pharmaceutical composition comprises miconazole or a salt thereof and luliconazole or a salt thereof; wherein miconazole or a salt thereof and luliconazole or a salt thereof provide potent antifungal activity, efficacy and patient compliance in treating vaginal fungal infections.
[0101] The vaginal pharmaceutical composition comprising miconazole or its salt and luliconazole or its salt for treating vaginal infection according to the present invention broadens the activity spectrum, improves the speed or degree of antifungal or antibacterial activity, and reduces the toxicity of the treatment of vaginal fungal infection.
[0102] In one embodiment, the present invention provides a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0103] In one embodiment, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof.
[0104] In one embodiment, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0105] The vaginal pharmaceutical composition comprising miconazole or its salt and luliconazole or its salt for treating vaginal infection according to the present invention is formulated into a dosage form selected from the following: vaginal suppositories, vaginal rings, douches, suppositories, tablets, soft capsules, tampons, foams, sprays, gels, creams, intrauterine contraceptive devices (IUDs), ointments, pastes, lotions, solutions, tinctures, powders, mousses, cleansers and mucoadhesive vaginal films, etc.
[0106] A vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
[0107] The vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof for treating vaginal infections may contain one or more pharmaceutically acceptable excipients selected from bases, emollients, lubricants, thickeners or thickeners, surfactants, solubilizers or emulsifiers or emulsifying substances, co-emulsifiers, preservatives, antioxidants, humectants, absorbents, penetration enhancers, opacifiers, chelating agents, gelling agents, acidifiers or alkalizers or buffers, flavors or fragrances, antifoaming agents, adhesives, bioadhesive polymers, vehicles and any other excipients known in the art for preparing pharmaceutical compositions.
[0108] Examples of bases according to the present invention include, but are not limited to, carnauba wax, cetyl alcohol, cetyl esters wax, emulsifying wax, aqueous lanolin, lanolin, lanolin alcohol, vegetable oils and animal fats; coconut oil, beeswax, olive oil, spermaceti, sesame oil, almond oil, alcohols, acids and esters; oleic acid, oleyl alcohol, palmitic acid, lauryl alcohol, lauraic acid, myristyl alcohol, ethyl oleate, isopropyl myristate, ethylene glycol, hydrogenated oils and sulfated oils; hydrogenated castor oil, cottonseed oil, hydrogenated sulfated castor oil, microcrystalline wax, liquid paraffin, petrolatum, polyethylene glycol, stearic acid, stearyl alcohol, white wax, yellow wax or a combination thereof.
[0109] Examples of emollients according to the present invention include, but are not limited to, waxes, fats, caprylic / capric triglyceride, castor oil, ceteareth-20, ceteareth-30, cetearyl alcohol, ceteth-20, cetostearyl alcohol, cetyl alcohol, cetearyl alcohol, cocoa butter, diisopropyl adipate, glycerin, glyceryl monooleate, glyceryl monostearate, glyceryl stearate, isopropyl myristate, isopropyl palmitate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffin, linoleic acid, mineral oil, oleic acid, white petrolatum, polyethylene glycol, polyethylene glycol fatty alcohol ether, polyoxypropylene 15-stearyl ether, propylene glycol stearate, squalane, stearic acid Alcohol polyether-2 or -100, stearic acid and urea, oils of natural origin (such as almond oil, coconut oil, olive oil, palm oil, peanut oil, etc.), fatty acids (such as lauric acid, myristic acid, palmitic acid and stearic acid), monohydric alcohol esters of fatty acids (such as ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, ethyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stearate, amyl stearate and isopentyl stearate), glycols (such as ethylene glycol, diethylene glycol, polyethylene glycol), branched fatty alcohols (such as lauryl alcohol, myristyl alcohol and stearyl alcohol) or combinations thereof.
[0110] Examples of lubricants according to the present invention include, but are not limited to, castor oil, mineral oil, paraffin oil, ispagol mucus, vitamin D, talc, or any mixture thereof. The amount of lubricant present in the composition may be about 0.1-15% by weight of the composition; preferably about 0.5-12% by weight; more preferably about 1-10% by weight.
[0111] Examples of thickeners or thickeners according to the present invention include, but are not limited to, carbomer, hydrogenated castor oil, methylcellulose, sodium carboxymethylcellulose, carrageenan, colloidal silicon dioxide, natural gums (e.g., gelatin, tragacanth and guar gum), hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene oxide, alginic acid, paraffin, cetostearyl alcohol, PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene sorbiton monoleate and poloxamer, polyvinyl pyrrolidone, various alcohols such as polyvinyl alcohol, ethanol or isopropanol, fumed silica or a combination thereof.
[0112] Examples of surfactants according to the present invention include, but are not limited to, ionic, cationic, and nonionic surfactants or any mixture thereof, and further selected from, but not limited to, one or more of the following surfactants: polysorbate, polysorbate 20, polysorbate 40, polysorbate 80, polysorbate 60, poloxamer, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulfate, propylene glycol monostearate, dodecylbenzene sulfonate, polyethylene glycol, PEG. 100 stearate, polyethylene glycol 6000 distearate, polyethylene glycol 1000 monohexadecyl ether, polyethylene glycol monostearate, polyethylene glycol 400 monostearate, polyethylene glycol fatty alcohol ether, polyethylene glycol 20 ceteareth ether, polyethylene glycol 40 stearate, PPG-26 oleate, sorbitan esters, sorbitan monolaurate, sorbitan monopalmitate, sorbitan palmitate, sorbitan sesquioleate, etc. or a combination thereof.
[0113] Examples of solubilizers or emulsifiers according to the present invention include, but are not limited to, almond oil PEG-6 esters, pegoxol-7 stearate, polysorbate 20, polysorbate 80, polysorbate 60, poloxamer, emulsifying wax, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulfate, propylene glycol monostearate, natural gums (such as gum arabic and tragacanth), monovalent and divalent soaps, lanolin, cholesterol or cholesterol esters, triethanolamine and its salts, dodecylbenzene sulfonate, diethylene glycol monoethyl ether, sodium docusate or mixtures thereof. The amount of solubilizer or emulsifier present in the composition is about 0.1-25% by weight of the composition; preferably 1-22% by weight.
[0114] Examples of co-emulsifiers according to the present invention include, but are not limited to, almond oil PEG-6 esters, propylene glycol stearate, hexadecyl hydroxyethylcellulose, poloxamer 407, polyglyceryl-2 stearate, or a combination thereof. The amount of co-emulsifier present in the composition is about 0.1-10% by weight of the composition; preferably 0.05 to 8% by weight.
[0115] Examples of preservatives according to the present invention include, but are not limited to: chorocresol, benzoic acid, butylated hydroxyanisole, phenylmercuric nitrate, benzyl alcohol, benzoic acid and its salts, boric acid, methyl paraben, propyl paraben, sodium acetate trihydrate and anhydrous sodium acetate, chlorhexidine, formaldehyde, glutaraldehyde, imidazolidinyl urea, triclosan, benzalkonium chloride, chloroxylenol or a combination thereof. The amount of preservative present in the composition can be about 0.001-6% by weight of the composition; preferably about 0.001-5% by weight; more preferably about 0.005-4.5% by weight.
[0116] Examples of antioxidants according to the present invention include, but are not limited to, butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate, polyols (such as sorbitol, xylitol and maltitol), natural extracts such as quince bark, or lactic acid or urea, lithium chloride, ascorbic acid, sodium metabisulfite, carotenoids, carotenes (such as alpha-carotene, beta-carotene and lycopene), chlorogenic acid, tocopherol, uric acid, zinc oxide, zinc sulfate or a combination thereof.
[0117] Examples of moisturizers according to the present invention include, but are not limited to, glycerin, triacetin, propylene glycol, polyethylene glycol, sorbitol solution, 1,2,6 hexanetriol, isopropyl myristate, petrolatum, isopropyl palmitate, hydrogenated castor oil, mineral oil, polyoxymethylene urea, potassium sorbate, or combinations thereof.
[0118] Examples of absorbents according to the present invention include, but are not limited to, magnesium carbonate, calcium carbonate, starch, cellulose and derivatives thereof, or combinations thereof.
[0119] Examples of penetration enhancers according to the present invention include, but are not limited to, propylene glycol, ethanol, isopropyl alcohol, oleic acid, polyethylene glycol, phospholipids, cyclodextrins, black pepper (piper nigrum), pyrrolidone, dimethyl sulfoxide (dmso), decyl methyl sulfoxide (dcms), terpenes (eucalyptol, eugenol, d-limonene, menthol, menthone), urea, or combinations thereof.
[0120] Examples of sunscreens according to the present invention include, but are not limited to, higher fatty alcohols (e.g., cetyl alcohol, stearyl alcohol, cetostearyl alcohol, eicosanol and behenyl alcohol), solid esters (e.g., cetyl palmitate, glyceryl laurate), various fatty acid derivatives (e.g., propylene glycol esters and polyethylene glycol esters), inorganic materials (e.g., magnesium aluminum silicate, zinc oxide, titanium dioxide or other sunscreens), or combinations thereof.
[0121] Examples of chelating agents according to the present invention include, but are not limited to, ethylenediaminetetraacetate, dimercaptopropanol, dimercaptosuccinic acid, penicillamine, deferoxamine, deferasirox, citric acid, maleic acid, phosphoric acid, or combinations thereof.
[0122] Examples of gelling agents according to the present invention include, but are not limited to, carbomer / carbopols, pemulen®, cellulose derivatives (e.g., methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, etc.), gels formed by glycerol or propylene glycol with suitable agents (e.g., natural gums (e.g., xanthan gum and tragacanth gum), fenugreek mucilage, pectin, poloxamers (Pluronic), alginates, gelatin, starch, polyvinyl alcohol, povidone), or combinations thereof.
[0123] Examples of acidifying or alkalizing agents or buffering agents according to the present invention include, but are not limited to, anhydrous and monohydrate citric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium sorbate, sodium dihydrogen phosphate and disodium hydrogen phosphate, triethanolamine, or combinations thereof.
[0124] Examples of flavors or fragrances according to the present invention include, but are not limited to, lavender, lemon, gardenia, hypoallergenic perfume, menthol, or combinations thereof.
[0125] Examples of the defoaming agent according to the present invention include, but are not limited to, cyclomethicone, dimethicone, and simethicone, or a combination thereof.
[0126] Examples of binders according to the present invention include, but are not limited to, natural gums (gum arabic, align gum, guar gum, tragacanth and xanthan gum, pectin and dextran) or combinations thereof.
[0127] Examples of bioadhesive polymers according to the present invention include, but are not limited to, ethylcellulose, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, or combinations thereof.
[0128] Examples of vehicles according to the present invention include, but are not limited to, purified water, hexylene glycol, propylene glycol, oleyl alcohol, propylene carbonate, mineral oil, almond oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, myristyl alcohol, octyldodecanol, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, polyethylene glycol, diethylene glycol monoethyl, glycofurol, benzyl alcohol, caprylic acid capric acid polyethylene glycol glyceride (labrasol), benzyl benzoate and ethyl oleate, diethylene glycol monoethyl ether, ethanol, polyoxyethylene castor oil ELP (cremophore ELP), solutol, diethylene glycol monoethyl ether (transcutol), capmul, captex or its mixture. Preferably, vehicle is water. Vehicle of the present invention can be present in a certain amount to supplement volume to a sufficient amount.
[0129] In one embodiment, the present invention provides a vaginal pharmaceutical composition for treating vaginal infection comprising:
[0130] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0131] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0132] iii) 0.1-15 % w / w of a lubricant;
[0133] iv) 0.1-25 % w / w of an emulsifier;
[0134] v) 0.1-10 % w / w of a co-emulsifier;
[0135] vi) 0.001-6 % w / w of a preservative; and
[0136] vii) QS medium
[0137] In one embodiment, the present invention provides a vaginal pharmaceutical composition comprising:
[0138] i) 0.1%-10% w / w of miconazole or a salt thereof;
[0139] ii) 0.01-5% w / w of luliconazole or a salt thereof;
[0140] iii) 0.1-15 % w / w of a lubricant;
[0141] iv) 0.1-25 % w / w of an emulsifier;
[0142] v) 0.1-10 % w / w of a co-emulsifier;
[0143] vi) 0.001-6 % w / w of a preservative; and
[0144] vii) Vehicles of qs.
[0145] In one embodiment, the present invention provides a method for preparing a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof, comprising:
[0146] (a) Water phase: dissolve the preservative in purified water, mix and heat at an appropriate temperature;
[0147] (b) lipid phase: mix the co-emulsifier, emulsifier, lubricant and preservative and heat at an appropriate temperature;
[0148] (c) cooling the lipid phase of step (b) at a suitable temperature and mixing the two active pharmaceutical ingredients (API) for 5-10 minutes;
[0149] (d) emulsifying by adding step (c) to step (a) and mixing for 10 minutes; and
[0150] (e) The cream obtained in step (d) was slowly mixed and cooled at room temperature.
[0151] A vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof for treating vaginal infection, wherein the vaginal pharmaceutical composition can be applied at least once daily or as directed by a healthcare provider.
[0152] The vaginal pharmaceutical composition according to the present invention can be applied to the affected area by hand or with a suitable applicator.
[0153] The vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or its salt and luliconazole or its salt, further comprises other pharmaceutically acceptable polymers mainly used to maintain appropriate viscosity of the formulation.
[0154] The vaginal pharmaceutical composition comprising miconazole or its salt and luliconazole or its salt for treating vaginal infection according to the present invention can be prepared by grinding, water milling, melting, chemical reaction, emulsification, cold method, dispersion, molding, compression, hand rolling and forming, pouring molding, wet granulation, dry granulation or direct tableting.
[0155] The concentrations of the active ingredients miconazole or its salt and luliconazole or its salt and other excipients, and the manufacturing process have been optimized so that the composition has maximum therapeutic efficacy in treating vaginal fungal infections with minimal or no side effects, and it leads to better patient compliance.
[0156] The synergistic effect of miconazole or its salt and luliconazole or its salt according to the present invention broadens its activity spectrum, increases the speed or degree of antifungal or antibacterial activity, and reduces the toxicity of the treatment of vaginal fungal infections.
[0157] The vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof was evaluated by pH determination, primary skin irritation test, visual appearance, viscosity, spreadability, stability studies, rheological studies, thermal behavior, saponification value and acid value.
[0158] The vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof for treating vaginal infection according to the present invention can be loaded for stability study according to the ICH guidelines.
[0159] The vaginal pharmaceutical composition comprising miconazole or its salt and luliconazole or its salt for treating vaginal infection according to the present invention can be packaged in a collapsible tube, a jar, a pot, a bottle or a single-dose package. The container material or packaging material of the present invention will not affect the quality of the preparation, nor will it allow any kind of diffusion into or through the container material into the preparation.
[0160] The vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof for treating vaginal infection according to the present invention can be labeled according to the requirements of Good Manufacturing Practice.
[0161] The following examples are provided to illustrate embodiments of the present invention. However, they are not intended to limit the scope of the present invention.
[0162] Example 1: Cream Base Method:
[0163] Serial Number Element % w / w 1. Miconazole nitrate 2.0 2. Luliconazole 1.0 3. Mineral oil 6.0 4. Almond Oil PEG-6 Esters 2.0 5. PEG-7 Stearate 14.0 6. Butylated Hydroxyanisole 0.015 7. benzoic acid 0.25 8. Purified water qs to 100
[0164] qs: sufficient
[0165] Manufacturing method:
[0166] 1. Water phase: Dissolve benzoic acid in purified water, mix, and heat at 65-75°C;
[0167] 2. Lipid phase: Mix almond oil PEG-6 ester, polyethylene glycol-7 stearate, mineral oil, butylated hydroxyanisole and heat at 65-75°C;
[0168] 3. Cool the phase of step 2 at 65°C and mix the two active pharmaceutical ingredients (APIs), miconazole nitrate and luliconazole, for 5-10 minutes;
[0169] 4. Add step 3 to step 1 and mix for 10 minutes to achieve emulsification, and
[0170] 5. Mix the prepared cream slowly and cool it at room temperature.
[0171] Physical parameters:
[0172] Serial Number parameter Observations 1. describe White - off-white, smooth and uniform cream 2. pH 3.50-5.00 3. Viscosity 1000-3000 cPs
[0173] Example 2: Cream Base with Variation of Emulsifier and Preservative Method:
[0174] Serial Number Element % w / w 1. Miconazole nitrate 1.0 2. Luliconazole 0.5 3. Mineral oil 6.0 4. Almond Oil PEG-6 Esters 2.0 5. PEG-7 Stearate 14.0 6. Butylated Hydroxyanisole 0.015 7. benzoic acid 0.25 8. Purified water qs to 100
[0175] qs: sufficient
[0176] Manufacturing method:
[0177] 1. Water phase: Dissolve benzoic acid in purified water, mix, and heat at 65-75°C;
[0178] 2. Lipid phase: Mix almond oil PEG-6 ester, polyethylene glycol-7 stearate, and mineral oil and heat at 65-75°C;
[0179] 3. Cool the phase of step 2 at 65°C and mix the two active pharmaceutical ingredients (APIs), miconazole nitrate and luliconazole, for 5-10 minutes;
[0180] 4. Add step 3 into step 1 and mix for 10 minutes to achieve emulsification, and
[0181] 5. Mix the prepared cream slowly and cool it at room temperature.
[0182] Physical parameters:
[0183] Serial Number parameter Observations 1. describe White - off-white, smooth and uniform cream 2. pH 3.50-5.00 3. Viscosity 1000-3000 cPs
Claims
1. A vaginal pharmaceutical composition for treating vaginal infection, comprising miconazole or a salt thereof and luliconazole or a salt thereof and one or more pharmaceutically acceptable excipients.
2. The vaginal pharmaceutical composition for treating vaginal infection according to claim 1, wherein the vaginal pharmaceutical composition comprises: i) 0.1%-10% w / w of miconazole or a salt thereof; ii) 0.01-5% w / w of luliconazole or a salt thereof; iii) 0.1-15 % w / w of a lubricant; iv) 0.1-25 % w / w of an emulsifier; v) 0.1-10 % w / w of a co-emulsifier; vi) 0.001-6 % w / w of a preservative; and vii) sufficient quantity (qs) of vehicle.
3. A vaginal pharmaceutical composition for treating vaginal infection as claimed in claim 1, wherein the vaginal infection is selected from yeast infection, bacterial vaginosis, trichomoniasis, sexually transmitted infection (STI), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis, atrophic vaginitis, etc.
4. A vaginal pharmaceutical composition comprising: i) miconazole or a salt thereof; ii) luliconazole or a salt thereof; and iii) one or more pharmaceutically acceptable excipients.
5. The vaginal pharmaceutical composition according to claim 4, comprising: i) 0.1%-10% w / w of miconazole or a salt thereof; ii) 0.01-5% w / w of luliconazole or a salt thereof; iii) 0.1-15 % w / w of a lubricant; iv) 0.1-25 % w / w of an emulsifier; v) 0.1-10 % w / w of a co-emulsifier; vi) 0.001-6 % w / w of a preservative; and vii) sufficient quantity (qs) of vehicle.
6. A vaginal pharmaceutical composition as described in any one of claims 1 or 4, wherein one or more pharmaceutically acceptable excipients are selected from bases, emollients, lubricants, thickeners or thickeners, surfactants, solubilizers or emulsifiers or emulsifying substances, co-emulsifiers, preservatives, antioxidants, humectants, absorbents, penetration enhancers, sunscreens, chelating agents, gelling agents, acidifiers or alkalizers or buffers, fragrances or aromatics, defoaming agents, adhesives, bioadhesive polymers and vehicles, etc. or combinations thereof.
7. The vaginal pharmaceutical composition of claim 1 or 4, wherein the composition is formulated into a dosage form selected from the group consisting of vaginal suppositories, vaginal rings, douches, suppositories, tablets, soft capsules, tampons, foams, sprays, gels, creams, intrauterine devices (IUDs), ointments, pastes, lotions, powders, solutions, tinctures, mousses, cleansers, and mucoadhesive vaginal films.
8. A method for preparing a vaginal pharmaceutical composition comprising miconazole or a salt thereof and luliconazole or a salt thereof, comprising: (a) Water phase: dissolve the preservative in purified water, mix and heat at an appropriate temperature; (b) lipid phase: mix the co-emulsifier, emulsifier, lubricant and preservative and heat at an appropriate temperature; (c) cooling the lipid phase of step (b) at a suitable temperature and mixing the two active pharmaceutical ingredients (API) for 5-10 minutes; (d) emulsifying by adding step (c) to step (a) and mixing for 10 minutes; and (e) The cream obtained in step (d) was slowly mixed and cooled at room temperature.
